A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

References

• Ludwig H, Van Belle S, Barrett-Lee P,. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer 2004;40: 2293-306
   PubMed Web of Science ®Google Scholar
• Nowrousian MR. Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM, editors. Rh-erythropoietin in cancer supportive treatment. New York: Marcel Dekker; 1996. p. 13-34
   Google Scholar
• Caro JJ, Salas M, Ward A,. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21
   PubMed Web of Science ®Google Scholar
• Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28 (2 Suppl 8):7-14
   PubMed Web of Science ®Google Scholar
• Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001;84:31-7
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland C,. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95
   PubMed Web of Science ®Google Scholar
• Gabrilove J, Cleeland C, Livingston R,. et al. Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82
   PubMed Web of Science ®Google Scholar
• Glaspy J, Jadeja J, Justice G,. et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
   PubMed Web of Science ®Google Scholar
• Littlewood T, Bajetta E, Nortier JWR,. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
   PubMed Web of Science ®Google Scholar
• Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-86
   PubMed Web of Science ®Google Scholar
• Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14:511-9
   PubMed Web of Science ®Google Scholar
• Stone P, Richards M, A'Hern R,. et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Am Oncol 2000;11:561-7
   Google Scholar
• Berndt E, Kallich J, McDermott A,. et al. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005;23:505-14
   PubMed Web of Science ®Google Scholar
• Walker RH. Award lectures and special reports: transfusion risk. Am J Clin Pathol 1987;88:374-8
   PubMed Web of Science ®Google Scholar
• Brand A. Immunological aspects of blood transfusions. Transpl Immunol 2002;10:183-90
   PubMed Web of Science ®Google Scholar
• Spirtos NM. Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol 2002;25:398-403
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology/American Society of Hematology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol 2008;26:132-49
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK,. et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31:290-9
   PubMed Web of Science ®Google Scholar
• Glaspy J, Henry D, Patel R,. et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
   PubMed Web of Science ®Google Scholar
• Egrie JC, Brown JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84:3-10
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B,. et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• Hedenus M, Adriansson M, San Miguel J,. et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
   PubMed Web of Science ®Google Scholar
• Canon J-L, Vansteenkiste J, Bodoky G,. et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology-v.1.2002: Cancer and Treatment-Related Anemia
   Google Scholar
• Yellen SB, Cella DF, Webster K,. et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74
   PubMed Web of Science ®Google Scholar
• Holzner B, Kemmler G, Greil R,. et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-73
   PubMed Web of Science ®Google Scholar
• Kallich JD, Tchekmedyian NS, Damiano AM,. et al. Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology 2002;16 (9 Suppl 10):117-24
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Gagnon D, Zagari M,. et al. Epoetin Alfa Study Group. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-53
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J,. et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Kallich JD, San Miguel J,. et al. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage 2006;31:317-25
   PubMed Web of Science ®Google Scholar
• Aranesp® summary of product characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/aranesp/ H-332-PI-en.pdf [last accessed 13 July 2007]
   Google Scholar
• Cella D, Eton DT, Lai F,. et al. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy anemia and fatigue scales. J Pain Symptom Manage 2002; 24:547-61
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M,. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-72
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C,. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-60
   PubMed Web of Science ®Google Scholar
• Smith Jr RE, Aapro MS, Ludwig H,. et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-50
   PubMed Web of Science ®Google Scholar
• Pirker R, Ramlau RA, Schuette W,. et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-9
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B,. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 2008; 299:914-24
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J,. et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407
   PubMedGoogle Scholar